As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Oct 16th, Hainan, China—The 15thAward of competitive and trustworthy listed companies in China was held in Sanya, Hainan. The theme of the forum was “the prospect of the capital market driven by the ‘double cycle’”. The attendees included experts and KOL from different industries and entrepreneurs from hundreds of successful listed companies. They gathered together to discuss risks, opportunities and expectations of the capital market under the influence of COVID-19.
Medicilon was invited as a newly successful listed company. At the event, Medicilon won “The best sustainable investable listed company Award”. Meanwhile, Mr. Wang Guolin, Secretary of the board of directors of the company, won the “gold medal Secretary of the board directors”. The award acknowledged the market performance and strategies Medicilon had had in the past. In the future, Medicilon, as the leading CRO for new drug research and development, will further develop and expand with the help of capital market and keep “Innovation Driven, Quality Focused”.